Development and clinical application of [11C]Verapamil-PET, a surrogate marker on p-glycoprotein expressio
- Conditions
- Diseases of the nervous system
- Registration Number
- KCT0000994
- Lead Sponsor
- Seoul National University Hospital
- Brief Summary
Results We completed analyses in 20 patients with epilepsy, 8 of 12 patients with drug resistant epilepsy and 10 healthy controls. In the Drug resistant epilepsy group, 8 patients had a significantly larger extent of asymmetry between ipsilateral and contralateral areas compared to healthy controls. Also one of 8 patient with drug resistant epilepsy who had nonlesional frontal lobe epilepsy showed that increasing asymmetry of SUVs over the entire time checked by dynamic PET. In the Drug sensitive epilepsy group, there was no significant difference with healthy controls. From the results achieved so far, we confirmed importance of p-glycoprotein expression in drug resistant epilepsy by a noninvasive method. [11C]Verapamil PET can be used as a surrogate marker of p-glycoprotein expression in patients with epilepsy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 30
Healthy controls ( age range 20-45 years)
patient age (> 15), diagnose as epilepsy
Subjects who take medicines that affect on the function of p-glycoproteins
Pregnancy or subject who feed the breast milk
Subjects who had severe renal disease or liver disease
Subjects who need treated by immunosuppressant or take immunosuppressant
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Efficacy of assessing p-glycoprotein expression in patients with epilepsy through [11C]-verapamil PET
- Secondary Outcome Measures
Name Time Method Side effect of cyclosporine, safety of [11C]-verapamil PET